Total Funding
76
47
Total FundingPost-IPO Equity raised
Growth Score
7 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
57238
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
- David Chang: President, CEO and Co-FounderPast Role: Hunt Club, GM, Expert Network
- Zachary Roberts: Executive Vice President of Research & DevelopmentPast Role: Instil Bio, Chief Medical Officer
About the Company
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and
advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
